Actos Important Safety Information
Links shared publicly online about this topic
FDA Reviewing Preliminary Safety Information On Actos (pioglitazone)
medicalnewstoday.com — “The U.S. Food and Drug Administration announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study des” View full resource at medicalnewstoday.com
Most Recently Shared on September 18, 2010 at 2:05 pm By:
FDA Reviewing Preliminary Safety Information On Actos (pioglitazone) http://mnt.to/3K23 #diabetes
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone)
diabetesincontrol.com — “Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.” View full resource at diabetesincontrol.com
Most Recently Shared on September 30, 2010 at 3:46 pm By:
AmDiabetesAssn Health Organization
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone) http://t.co/owEq4cN via @AddThis
FDA Reviewing Safety Information on Actos - WSJ.com
online.wsj.com — “The Food and Drug Administration said Friday it has started a safety review of Takeda Pharmaceutical Co.'s diabetes drug Actos, looking at links to bladder cancer.” View full resource at online.wsj.com
Most Recently Shared on September 19, 2010 at 10:13 pm By:
FDA Reviewing Safety Information on Actos http://on.wsj.com/dyA7nV
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone) - Drugs.com MedNews
drugs.com — “The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary result” View full resource at drugs.com
Most Recently Shared on September 20, 2010 at 2:16 pm By:
Drugs and Devices OW OW Health
FDA Reviewing Preliminary Safety Information on Actos (pioglitazone): SILVER SPRING, Md., Sept. 17 /PRNewswir... http://bit.ly/dctUns #drug
FDA reviewing preliminary safety information on Actos http://ow.ly/2FYe9
fda.gov — “FDA reviewing preliminary safety information on Actos http://ow.ly/2FYe9” View full resource at fda.gov
Most Recently Shared on September 17, 2010 at 6:26 pm By:
eyeonfda Pharma and Health Lawyer
FDA reviewing preliminary safety information on Actos http://ow.ly/2FYe9
FDA reviewing preliminary safety information on Actos (pioglitazone) - Pharma Marketing Network Forums
forums.pharma-mkting.com — “FDA reviewing preliminary safety information on Actos (pioglitazone) Regulatory Affairs” View full resource at forums.pharma-mkting.com
Most Recently Shared on September 18, 2010 at 4:08 pm By:
FDA reviewing preliminary safety information on Actos: http://bit.ly/9h0YOB
Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer - Drugs.com MedNews
drugs.com — “UPDATED 06 15 2011 Use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Inform” View full resource at drugs.com
Most Recently Shared on June 16, 2011 at 4:05 pm By:
Drugs and Devices OW OW Health
Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer: [UPDATED 06/15/2... http://bit.ly/kLBWRn #drug
FDA Reviewing Preliminary Safety Information On Actos (pioglitazone) | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com
keyvive.com — “FDA Reviewing Preliminary Safety Information On Actos (pioglitazone) | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com
Most Recently Shared on September 20, 2010 at 9:38 pm By:
FDA Reviewing Preliminary Safety Information On Actos (pioglitazone): The U.S. Food and Drug… http://goo.gl/fb/M6Cz7
Important Safety Information
strattera.com — “Important Safety Information” View full resource at strattera.com
Most Recently Shared on April 16, 2010 at 9:51 pm By:
Strattera is commonly recommended for adult ADHD, but it's not for everyone. Review the important safety information. http://bit.ly/9CRjbo
Important Safety Information
rituxan.com — “Important Safety Information about RITUXAN. Indications and Important Safety Information RITUXAN® (Rituximab) is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent, Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy, Non-pr” View full resource at rituxan.com
Most Recently Shared on March 10, 2012 at 11:42 pm By:
What Should You Know About RITUXAN? http://t.co/w8NMjshM Be careful joining clinical trials with this drug #diabetes
**IMPORTANT safety... | Facebook
facebook.com — “From Womb to Cradle Doula Services wrote: **IMPORTANT safety information for... Join Facebook to connect with From Womb to Cradle Doula Services and others you may know.” View full resource at facebook.com
Most Recently Shared on June 20, 2010 at 1:47 am By:
**IMPORTANT safety information for parents and parents-to-be! Please read and share! http://fb.me/tia7VZfU
FDA plan aims to increase import safety
health.yahoo.net — “U.S. food and drug regulators would share more information with their foreign counterparts as part of a multifaceted strategy to police the safety of millions of imported goods.” View full resource at health.yahoo.net
Most Recently Shared on June 20, 2011 at 3:48 pm By:
Jennifer Ann Grisso Nurse and Active Health Library
FDA plan aims to increase import safety: U.S. food and drug regulators would share more information with their f... http://bit.ly/llvUv5
FDA plan aims to increase import safety
health.yahoo.net — “U.S. food and drug regulators would share more information with their foreign counterparts as part of a multifaceted strategy to police the safety of millions of imported goods.” View full resource at health.yahoo.net
Most Recently Shared on June 20, 2011 at 6:25 pm By:
Jane Anderson Healthy Eating Advisor
FDA plan aims to increase import safety http://bit.ly/kYkvEv
Longer-term use of pioglitazone associated with an increased risk of bladder cancer - - Drug Topics
drugtopics.modernmedicine.com — “FDA published an online safety communication on June 15, informing prescribers and patients that pioglitazone (Actos, Takeda Pharmaceuticals America Inc., Deerfield, Illinois) use may be associated with a 20% to 40% increased hazard of new bladder cancer.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on June 22, 2011 at 8:37 pm By:
Drugs and Devices OW OW Health
Longer-term use of pioglitazone associated with an increased risk of bladder cancer: FDA published an online saf... http://bit.ly/myRyc6
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MNT Diabetes News
The latest diabetes news published daily. Articles from research centers, universities and prestigious journals.
-
AmDiabetesAssn
Changing the future of diabetes one event at a time
-
WSJ Health
Health news coverage from the Wall Street Journal
Advertisement
